title: Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.
abstract: Post hoc analysis of the phase 2b Step study evaluating a recombinant adenovirus serotype 5 (rAd5)-based HIV-1 vaccine candidate suggested a potential increased risk of HIV-1 acquisition in subjects who were baseline Ad5 seropositive and uncircumcised. These concerns had a profound impact on the HIV-1 vaccine development field, although the mechanism underlying this observation remains unknown. It has been hypothesized that rAd5 vaccination of baseline Ad5-seropositive individuals may have resulted in anamnestic, vector-specific CD4(+) T lymphocytes that could have trafficked to mucosal sites and served as increased targets for HIV-1 infection. Here we show that Ad5-specific CD4(+) T lymphocyte responses at mucosal sites following rAd5-Gag/Pol/Nef vaccination were comparable in rhesus monkeys with and without baseline Ad5 immunity. Moreover, the total cellular inflammatory infiltrates and the CD3(+), CD4(+), HLA-DR(+), Ki67(+), and langerin(+) cellular subpopulations in colorectal and foreskin mucosa were similar in both groups. Thus, no greater trafficking of Ad5-specific CD4(+) T lymphocytes to mucosal target sites was observed following rAd5 vaccination of rhesus monkeys with baseline Ad5 immunity. These findings from this nonhuman primate model provide evidence against the hypothesis that recruitment of vector-specific target cells to mucosal sites led to increased HIV-1 acquisition in Ad5-seropositive, uncircumcised vaccinees in the Step study.
authors.affiliation: New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts 017721, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Masek-Hammerman
authors.forename: Hualin
authors.initials: H
authors.lastname: Li
authors.forename: Jinyan
authors.initials: J
authors.lastname: Liu
authors.forename: Peter
authors.initials: P
authors.lastname: Abbink
authors.forename: Annalena
authors.initials: A
authors.lastname: La Porte
authors.forename: Kara L
authors.initials: KL
authors.lastname: O'Brien
authors.forename: James B
authors.initials: JB
authors.lastname: Whitney
authors.forename: Angela
authors.initials: A
authors.lastname: Carville
authors.forename: Keith G
authors.initials: KG
authors.lastname: Mansfield
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology*; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology*; D052816:Foreskin / Q000166:cytology / Q000276:immunology / Q000821:virology; D005822:Genetic Vectors; D015658:HIV Infections / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D015497:HIV-1; D006801:Humans; D018928:Immunity, Mucosal; D007413:Intestinal Mucosa / Q000166:cytology / Q000276:immunology / Q000821:virology; D008253:Macaca mulatta; D008297:Male; D023421:Models, Animal; D018448:Models, Immunological; D009092:Mucous Membrane / Q000166:cytology / Q000276:immunology* / Q000821:virology*; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics
chemical_list: D016915:AIDS Vaccines; D014614:Vaccines, Synthetic